Ozempic and GLP-1 Medicines Show Promise but Bariatric Surgery Delivers Greater Weight Loss Results

Ozempic and similar glucagon like peptide 1 medicines remain at the center of the weight loss conversation this week, as new research and renewed celebrity attention highlight both their promise and their limits. According to a January report from the American Society for Metabolic and Bariatric Surgery, scientists reviewing records from more than fifty thousand patients found that people who had bariatric surgery lost about five times more weight over two years than those using weekly glucagon like peptide 1 medicines such as semaglutide, the active ingredient in Ozempic. The analysis, presented at the societys annual scientific meeting and summarized by Science Daily, showed surgery patients averaging roughly fifty eight pounds of weight loss, compared with about twelve pounds for people prescribed Ozempic or related drugs for at least six months. Even among those who stayed on these medicines continuously for a full year, average loss reached only about seven percent of body weight, much lower than the surgical group, underscoring how hard it is for many people to stay on these drugs over time because of cost, side effects, or supply issues. At the same time, obesity specialists quoted this week by Fox News Digital say they expect a major shift in how Ozempic style treatments are used. Rather than being seen only as weight loss shots, doctors are increasingly framing them as whole body metabolic medicines that can lower cardiovascular risk and protect the kidneys and liver, with next generation combinations already in development that may bring greater and more durable weight loss with easier dosing, including daily pills and, in trials, long lasting implants. Against this medical backdrop, Oprah Winfrey continues to shape how many listeners think about Ozempic and weight. In a new People magazine cover story highlighted by AOL in the last few days, she describes her decision to start a glucagon like peptide 1 medicine about two and a half years ago as part of accepting that she lives with the disease of obesity rather than a simple failure of discipline. She explains that understanding obesity as something rooted in genes and biology allowed her to stop blaming herself for decades of weight cycling. Oprah does not name a specific brand in that piece, but she speaks directly to people who see themselves in her story, saying that if obesity runs in your family, it is not your fault and that access to accurate information about medicines, lifestyle changes, and risks should guide decisions, not shame. She also notes that even with medication she still eats carefully and exercises most days, and she expects to remain on a glucagon like peptide 1 treatment long term. For listeners, the message from both the new data and Oprahs comments is that Ozempic and related medicines can be powerful tools, but they are not magic fixes and they work best as part of an ongoing plan that may include surgery, structured exercise, and long term medical follow up. Thanks for listening, please subscribe, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai

This content was created in partnership and with the help of Artificial Intelligence AI